Psychedelic Therapy in Belgium: Every Legal Route (2026)

If you are considering psychedelic-assisted treatment in Belgium — for yourself or for someone close to you — everything runs through hospitals. The one reimbursed route, esketamine, is administered in hospital with your insurer approving each patient in advance; off-label ketamine lives inside hospital psychiatry rather than private clinics; and the only legal contact with psilocybin is inside two hospital-run trials. This guide covers who qualifies for each route, how to start, what it costs, and what to realistically expect; you can begin orienting yourself with our eligibility check.

TL;DR Spravato (esketamine) has been reimbursed since June 2021 under INAMI/RIZIV's Chapter IV rules: treatment is hospital-administered, and your health insurer's advising physician must approve your file before you start — the criteria are a moderate-to-severe depressive episode and at least two failed antidepressants. Belgium has effectively no private ketamine market; off-label intravenous ketamine is used in some hospital psychiatric settings under prescriber responsibility. Psilocybin and MDMA are trial-only: Ghent University Hospital is recruiting for a psilocybin study in treatment-resistant depression and CHU Brugmann in Brussels for one in severe alcohol use disorder, while no Belgian MDMA trial is recruiting as of July 2026.

At a glance

Route	Substance	Status in Belgium	Who qualifies	Cost
Reimbursed esketamine	Esketamine (Spravato)	Reimbursed since June 2021 (Chapter IV); running	Moderate-to-severe depressive episode with at least two failed antidepressants; per-patient prior authorization	Covered once the insurer's advising physician approves
Hospital ketamine (off-label)	Ketamine	Legal off-label practice inside hospital psychiatry; no private clinic market	Hospital team's assessment, typically resistant depression or acute severe suicidal distress	Within hospital care; no dedicated reimbursement as an antidepressant
Psilocybin therapy	Psilocybin	Trial-only; two recruiting hospital studies	Study-specific criteria (Ghent: treatment-resistant depression; Brussels: severe alcohol use disorder)	Free within the trial
MDMA therapy	MDMA	Trial-only; no trial recruiting	—	—
Clinical trials	Psilocybin, ketamine, esketamine	18 tracked, 4 active	Study-specific criteria	Free

Full coverage details: Is Spravato reimbursed in Belgium?

Esketamine (Spravato): the reimbursed hospital route

Since June 2021, esketamine nasal spray is reimbursed in Belgium under Chapter IV of the INAMI/RIZIV medicines rules (CBIP/BCFI) — the chapter for medicines that need prior authorization. Three things define the route:

The criteria: a moderate-to-severe depressive episode that has not responded to at least two antidepressants taken at adequate dose and duration, with esketamine given in combination with an SSRI or SNRI.
The gatekeeper: reimbursement is approved per patient, in advance, by the advising physician (médecin-conseil / adviserend arts) of your health insurance fund (mutualité / ziekenfonds). The hospital submits your file; the advising physician reads your documented treatment history against the criteria before the first dose is scheduled.
The setting: Spravato is classified as a hospital-use medicine in Belgium (CBIP), so administration and the roughly two-hour observation period happen in a hospital psychiatric service, not at a pharmacy or private office.

Access pathway in Belgium: GP or psychiatrist, hospital psychiatric department, prior authorization by the insurer's advising physician, hospital-administered treatment with public coverage

How to start: Begin with your GP or treating psychiatrist and ask for a referral to a hospital psychiatric department that runs an esketamine program — Belgian university hospitals took part in the international esketamine development trials, so the infrastructure is established. The practical currency is a written treatment history: every antidepressant tried in the current episode, with substance, dose, duration and outcome. Ask the hospital to file the prior-authorization request early; in pre-approval systems like Belgium's this step can add several weeks, and it runs on your documentation. For how Belgium's arrangement compares across the continent, see our Europe-wide reimbursement map.

Cost: Once the advising physician approves, the medicine is covered; treatment happens within normal hospital billing, so ask the service up front about any facility or consultation charges beyond standard co-payments.

Ketamine: no private market, but a real hospital practice

Racemic ketamine is an authorized anaesthetic in Belgium, and the national medicines reference CBIP documents its off-label intravenous use in resistant depression and acute severe suicidal distress as an existing clinical practice under prescriber responsibility (CBIP). Two caveats apply. First, this is not an approved antidepressant indication, and there is no dedicated reimbursement route for psychiatric ketamine; where it happens, it happens inside hospital care and hospital budgets. Second, Belgium has effectively no private ketamine clinic market: unlike Germany, the UK or Austria, no standalone Belgian ketamine clinic is listed in our directory, and the ecosystem analyses reach the same conclusion — this is a hospital country.

In practice: if ketamine is a plausible option in your situation, the conversation belongs with a hospital psychiatrist, framed by your treatment history, not with a commercial provider. Be wary of anyone selling ketamine therapy privately in Belgium; the legitimate practice sits inside hospital psychiatry.

Psilocybin and MDMA: trial-only

Psilocybin, psilocin, MDMA, LSD, DMT and mescaline are expressly listed in Annex IIA of Belgium's narcotics framework, maintained by the federal medicines agency FAMHP under the 1921 drug law and the 2017 Royal Decree (FAMHP); the consolidated annexes valid from 29 March 2026 reaffirm that status. None has a Belgian marketing authorization, no compassionate-use or medical-need program for any psychedelic is open, and FAMHP's own guidance says patients should be considered for clinical trials first. Anyone offering psilocybin or MDMA therapy commercially in Belgium is operating illegally.

The trials, though, are running: Belgium currently has two recruiting psilocybin studies, both hospital-run:

Ghent: Ghent University Hospital is recruiting for PSIHOS-D (NCT06378229), a Phase 2 study of psilocybin-assisted therapy for hospitalized patients with treatment-resistant depression.
Brussels: CHU Brugmann is recruiting for a Phase 2 study of psilocybin-assisted therapy for severe alcohol use disorder (NCT06160232), run within an inpatient rehabilitation setting.

No Belgian MDMA trial is recruiting as of July 2026. If MDMA-assisted therapy matters to you, the realistic options are watching the registries for new Belgian studies or considering trial sites elsewhere in Europe — our trials guide explains how to search and what participation involves.

Clinical trials in Belgium

The research route is unusually deep for a country this size: Blossom tracks 18 trials connected to Belgium, four of them active (country report), and the ecosystem runs through university hospitals in Brussels, Ghent, Leuven and Liège. Beyond the two recruiting psilocybin studies above, Belgian groups run ketamine research in neurology and critical care (Leuven, Liège), and Belgian sites contributed to the pivotal esketamine programs that underpin today's reimbursed route. Brussels is also home to PAREA, the Psychedelic Access and Research European Alliance, which works on European-level access policy.

Participation is free and legal, but screening is strict and enrolment is never guaranteed; both recruiting studies are built around inpatient settings with thorough medical and psychiatric assessment. See the trials guide for how phases, placebo and consent work, browse trial sites in Belgium, and search ClinicalTrials.gov for current listings.

What to expect in treatment

Medically reviewed by Dr. Amy Reichelt, PhD, 31 July 2026 — this section and the risks section below.

These routes share a shape — medical screening, supervised administration, structured follow-up — but they are not interchangeable: the indication, the schedule, the staffing and the strength of the evidence all differ depending on whether you are prescribed Spravato (esketamine), given ketamine, or entering a legal psychedelic-assisted therapy route, where your country has one. What every route has in common is where it starts. Treatment begins with a screening appointment: the clinician reviews your psychiatric and medication history, checks your cardiovascular health and current medicines, and confirms the diagnosis before anything is scheduled. This is also where contraindications are caught.

On a Spravato day you self-administer the nasal spray in the practice or clinic under supervision, then stay for an observation period of roughly two hours while staff monitor blood pressure, heart rate, sedation, dissociation, breathing and overall recovery. Dissociation, dizziness, sedation, nausea and a temporary rise in blood pressure are common — though they do not occur in everyone — and settle as the drug clears. You must not drive, operate machinery or undertake anything hazardous until the following day, after a night's sleep, so arrange transport home. Induction is typically more frequent at first and then tapers based on measured response. Under the European label, Spravato for treatment-resistant depression is taken alongside a continuing oral SSRI or SNRI antidepressant.

A ketamine infusion for depression is an off-label use of the drug. It is usually given intravenously over about 40 minutes, with vital-sign and psychological monitoring and a recovery period afterwards. Some services offer ketamine-assisted psychotherapy (KAP), which wraps the dosing in preparation and integration sessions with a therapist; others provide ketamine as a medical antidepressant treatment with no psychotherapy component at all, which is worth establishing before you book. Where a legal psychedelic-assisted therapy route exists — and what that route is depends on the country: a clinical trial in most, a regulated programme or compassionate-use scheme in a few — dosing days are long and closely supervised by trained clinical staff, and sit inside a broader plan of preparation, general psychiatric care and integration. In every setting the medicine is one part of the plan: screening, monitoring and follow-up reduce risk but cannot eliminate it, and psychotherapy or integration may help you make sense of what the treatment brings up and apply it afterwards.

Risks and who should not start

These treatments are generally well tolerated under supervision, but they are not for everyone, which is exactly what screening is for. Common, transient effects during or shortly after a session include dissociation (a detached, dreamlike feeling), nausea, mild perceptual changes, and a short-lived rise in blood pressure and heart rate; these resolve as the drug is metabolised. Treatment may be inappropriate, or require particular caution and specialist evaluation, when any of the following apply:

Uncontrolled hypertension or significant cardiovascular instability, including a history of aneurysmal vascular disease. This is a contraindication for Spravato, because of the temporary rise in blood pressure; the other treatments carry their own cardiovascular assessment.
A personal or family history of psychosis or bipolar disorder — a particular caution for classic psychedelics such as psilocybin, which legal programmes screen for carefully.
Pregnancy or breastfeeding.
Current uncontrolled substance use, a history of ketamine misuse, or a high risk of compulsive use — any of these may make treatment inappropriate or require specialist assessment.

A responsible provider screens for all of these before the first dose. Careful screening, monitoring and follow-up reduce risk; they do not remove it. If a clinic is willing to treat you without that assessment, treat it as a warning sign — see our clinic-choice guide. To see who is listed near you, browse providers in Belgium.

Reviewer's note. Ketamine, Spravato (esketamine) and psilocybin-assisted therapies share common elements such as screening, supervision and follow-up, but they should not be presented as interchangeable. Each has distinct indications, contraindications, monitoring requirements and levels of evidence. Spravato follows a regulated treatment pathway, while IV ketamine is generally used off-label and psilocybin therapies remain largely investigational. Importantly, careful screening and clinical monitoring reduce risk but do not eliminate it.

— Dr. Amy Reichelt, PhD, neuroscientist, chartered psychologist and psychotherapist, PsyAccess review board

Frequently asked questions

How does the Chapter IV prior authorization work, and how long does it take?

The hospital psychiatric service submits your file — diagnosis plus the documented failed treatments — to your insurance fund, whose advising physician approves or refuses reimbursement before treatment starts. Budget several weeks and ask the hospital to file early; the quality of your treatment documentation is usually what decides both the outcome and the speed.

Do I pay anything for Spravato in Belgium?

Once your file is approved, the medicine is reimbursed and treatment runs within normal hospital billing — expect standard co-payments and possibly facility charges, and ask the service for the full picture up front. Without prior authorization there is no reimbursement, so do not start on a promise that paperwork will follow.

Can I get ketamine infusions at a private clinic in Belgium?

Effectively no — Belgium has no meaningful private ketamine market. Off-label ketamine for resistant depression or acute suicidal distress is an established but hospital-based practice under prescriber responsibility. If you see it advertised commercially in Belgium, be cautious.

Is psilocybin therapy legal in Belgium?

Only inside an authorized trial. Psilocybin is listed in the FAMHP annexes, and the two legal doors are the Ghent study in treatment-resistant depression and the Brussels study in severe alcohol use disorder, both recruiting. There is no compassionate-use program, and commercial offers are illegal.

Can I join the Ghent or Brussels psilocybin trials?

If you match the study populations — hospitalized treatment-resistant depression (Ghent) or severe alcohol use disorder in an inpatient rehabilitation setting (Brussels) — you can be screened, ideally via a referral from your treating clinician through the registry contacts. Screening is strict, criteria are protocol-specific, and enrolment is never guaranteed.

Is MDMA-assisted therapy available in Belgium?

Not outside research, and no Belgian MDMA trial is recruiting as of July 2026. MDMA is expressly listed in the FAMHP annexes with no authorized medical use. Watch the registries or consider trial sites elsewhere in Europe.

Sources

This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Reimbursement rules and trial availability change; always verify current requirements with your mutualité/ziekenfonds, the treating hospital, or a licensed clinician who knows your history. If you are in crisis, contact your local emergency number or a crisis line immediately.

This guide awaits review by a licensed medical professional.

Psychedelic Therapy in Belgium: Every Legal Route in 2026

On this page